FDA Approves First Ever RSV Vaccine In Adults: Interviews With Dr. Katie Sharff (Photo) - 05/17/23
PORTLAND, Ore. (May 17, 2023): On May 3 the U.S. Food and Drug Administration approved the first respiratory syncytial virus (RSV) vaccine for ages 60-older for use in the U.S, and since then many people have been calling Kaiser Permanente to ask when they can get it.
Dr. Katie Sharff, Chief of Infectious Disease for Kaiser Permanente Northwest, says the approval of the RSV vaccine Arexvy is great news, though the vaccine will not be available until fall. “The CDC needs to provide clinical guidance first and then vaccine will need to be distributed, so it may take a little longer than some people expect. But it’s still great news because respiratory viruses like RSV should be taken seriously, especially in older adults.”
In the U.S. alone, the CDC estimates between 60,000-160,000 older adults are hospitalized by RSV every year, and somewhere between 6,000 to 14,000 deaths are attributed to RSV in adults 65 and older. “The virus can be life-altering in older adults because it can cause lower respiratory tract disease and life-threatening pneumonia. Furthermore, it can cause other underlying health conditions to worsen,” said Dr. Sharff, “causing worsening of heart failure or COPD.”
Additionally, there is an RSV vaccine that could be given to pregnant people to prevent severe RSV disease in infants that will likely seek FDA approval in August. As we saw with last season, RSV infection can cause significant burden in infants and young children with an estimated 58,000 hospitalizations annually in children under 5 years old in the U.S.
Many people are eagerly awaiting the vaccines, especially after last year’s long and severe RSV season. “We need to remain patient, but we expect the vaccine will be available for distribution this fall, which will be just in time for the typical cold/flu/RSV season.
Interviews available:
Dr. Katie Sharff, Chief of Infectious Disease for Kaiser Permanente Northwest, is available for Zoom/phone interviews on Thursday, May 18 from 11 a.m.-noon and 1:30-2:30 p.m. Contact Karen Vitt to schedule.
Dr. Sharff is prepared to discuss:
• What we know about the newly approved RSV vaccine Arexvy – who is it for? What did the studies show?
• When do we expect the vaccine to become available?
• Are there other RSV vaccines on the way for older adults?
• What about RSV vaccines to protect infants? Who is it for? What did the data show?
• Health concerns around RSV, especially for older adults.
• Why respiratory diseases should be taken seriously.
ABOUT KAISER PERMANENTE
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America’s leading health care providers and not-for-profit health plans. Founded in 1945, Kaiser Permanente has a mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve 12.6 million members in 8 states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists, and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery, and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education, and the support of community health.
For more information, please visit: about.kaiserpermanente.org
